Keene v. United States

81 F.R.D. 653, 26 Fed. R. Serv. 2d 1231, 1979 U.S. Dist. LEXIS 14465
District Court, S.D. West Virginia·Decided February 14, 1979·No. Civ. A. No. 76-0382·Published·Cited by 2 cases

Opinion

MEMORANDUM OPINION AND ORDER

HADEN, District Judge.

In this action Plaintiffs seek declaratory and injunctive relief to establish their right to obtain and use laetrile (Vitamin B17, amygdalin) without governmental interference for the purpose of treating cancer. The action was instituted in October, 1976, on behalf of the named Plaintiffs1 and a purported class of similarly situated individuals. By this Court’s order of February 18, 1977, the following class was conditionally certified pursuant to Rule 23(b)(2) of the Federal Rules of Civil Procedure:

“All those persons who, having been diagnosed as afflicted with terminal cancer, and who desire to use laetrile as part of their treatment, and who because of law [655]*655or government regulation have been unable to obtain laetrile in adequate quantities for alleged therapeutic purposes.”

Plaintiffs contend that the right of privacy founded in the United States Constitution encompasses the right of a person with terminal cancer to elect, in consultation with his physician, to take laetrile. Asserting this argument before the Court, the Plaintiffs have moved for summary judgment. Defendants have moved for dismissal of the instant action. They have directed the Court’s attention to litigation originating in the United States District Court for the Western District of Oklahoma, apparently involving the same plaintiff class as certified herein, the same defendants, and in which the same issues have been and are being litigated. Rutherford v. United States of America, 399 F.Supp. 1208 (W.D.Okl.1975), aff’d and remanded, 542 F.2d, 1137 (10th Cir. 1976), on remand, 424 F.Supp. 105 (W.D.Okl.1977),429 F.Supp. 506 (W.D.Okl.1977), 438 F.Supp. 1287 (W.D.Okl.1977) , aff’d on other grounds, Rutherford v. United States, 582 F.2d 1234 (10th Cir. 1978).2

In support of their motion to dismiss, Defendants argue: (1) that in Rutherford, 438 F.Supp. 1287, the plaintiff class was awarded the relief sought herein and, therefore, that judgment is binding on all members of the class in the case at bar; and (2) that the interests of “judicial economy” require that this action be dismissed inasmuch as the interests of the Plaintiff class herein have been adequately asserted in the Rutherford proceeding. Defendant’s motion compels this Court to examine the character of the Rutherford litigation in order to determine the effect, if any, of that action upon the case at bar.

I.

A final judgment on the merits in a class action generally is binding on all members of the class. Sosna v. Iowa, 419 U.S. 393, n. 3, 95 S.Ct. 553, 42 L.Ed.2d 532 (1975); Advisory Committee Note to Rule 23(c)(3), 28 U.S.C.App. pp. 7765-66, 39 F.R.D. 69, 105-106; 7A Wright & Miller, Federal Practice and Procedure: Civil § 1789; see also Restatement of Judgments § 86 (1942). Such a judgment is binding on all members of the class, whether of a plaintiff or a defendant class, without regard to whether the judgment is favorable to the class. 3B Moore’s Federal Practice, ¶¶ 23.11, 23.60; 2 Newberg, Class Actions, § 2755; Rucker v. Willis, 358 F.Supp. 425 (E.D.N.C.), aff’d. on other grounds 484 F.2d 158 (1973). Nevertheless, a judgment in a purported class action will not be held to be binding upon absent, unnamed class members unless there has been compliance with the terms of Rule 23, Federal Rules of Civil Procedure, and with due process requirements. See generally, 2 Newberg, Class Actions § 2752. Therefore, whether the judgment in the Rutherford litigation precludes this Court from reaching the substantive issues raised herein is a matter for determination by this Court. See Eisen v. Carlisle and Jacquelin, 391 F.2d 555, 563 (2nd Cir. 1968); Gonzales v. Cassidy, 474 F.2d 67 (5th Cir. 1975); 2 Newberg, Class Actions § 2755. Application of these principles requires this Court to determine the following issues: (1) whether Plaintiffs in the case at bar are members of the plaintiff class in Rutherford; and, if so, (2) whether plaintiffs in Rutherford have asserted the same cause of action asserted by Plaintiffs herein; and, if so, (3) whether the proceedings in Rutherford comported with the requirements of due process and Rule 23 so that Plaintiffs herein are bound by the final judgment in Rutherford.

II.

The plaintiff class in Rutherford is comprised of “terminally ill cancer patients.” Rutherford, 429 F.Supp. 506, 509; 438 F.Supp. 1287; 582 F.2d 1235, 1236 (10th [656]*656Cir., 1978). In the order certifying the class, Judge Bohanon noted that certification was proper because the requirements of Rule 23(a) were met and because the “defendants have acted on grounds generally applicable to the class in a way that renders injunctive relief proper.” 429 F.Supp. 506, 508. The plaintiff class in Rutherford, therefore, was certified pursuant to Rule 23(b)(2). Although the phrasing of the certification order herein is not identical to that in Rutherford, it is clear peradventure, that the two classes are identical. Cf. Acree v. Airline Pilots Association, 390 F.2d 199, 202 (5th Cir. 1968), cert, denied, 393 U.S. 852, 89 S.Ct. 88, 21 L.Ed.2d 122.

The defendants in Rutherford are the same as the Defendants herein. Further, review of the various published opinions in Rutherford demonstrates that the cause of action asserted by the plaintiff class in that case is identical to the Plaintiffs’ 'cause herein: both challenge the validity of the United States Government’s prohibition of laetrile. Indeed, Judge Bohanon ruled on the precise constitutional claim here at issue and held in favor of the plaintiff class:

“By denying the right to use a nontoxic substance [laetrile] in connection with one’s own personal health-care, FDA has offended the constitutional right of privacy.” 438 F.Supp. 1287, 1301 (footnote omitted).

In accordance with that holding, Judge Bo-hanon ordered the defendants and their agents enjoined and restrained from, inter alia:

“Interfering with the use of Laetrile (Amygdalin) for the care or treatment of cancer by a person who is, or believes he is, suffering from the disease.” 438 F.Supp. 1287, 1301.

On review, the Court of Appeals for the Tenth Circuit stated the issue to be:

“[W]hether the plaintiffs, a class of terminally ill cancer patients, should be allowed to acquire Laetrile for their own use intravenously despite the Act’s [the Federal Food, Drug and Cosmetic Act, 21 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Keene v. United States, 81 F.R.D. 653, 26 Fed. R. Serv. 2d 1231, 1979 U.S. Dist. LEXIS 14465 (S.D.W. Va. 1979).

81 F.R.D. 653 (Keene v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Nichols v. Merrill Lynch, Pierce, Fenner & Smith, Inc.
821 F. Supp. 1254 (M.D. Tennessee, 1992)